MARKET

MNPR

MNPR

Monopar Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.00
+0.14
+2.90%
Closed 16:00 10/20 EDT
OPEN
4.910
PREV CLOSE
4.860
HIGH
5.04
LOW
4.910
VOLUME
2.25K
TURNOVER
--
52 WEEK HIGH
48.00
52 WEEK LOW
4.770
MARKET CAP
53.69M
P/E (TTM)
-11.7643
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Monopar Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020
WILMETTE, Ill., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) today announced that Chandler D. Robinson, MD, Chief Executive Officer, will present a corporate update at the H.C. Wainwright 22nd Annual Global Investment Conference, Healthcare & Biotech Track. The conference
GlobeNewswire · 09/14 13:30
Monopar And NorthStar Radioisotopes Collaborate With Texas Lung Injury Institute For Testing Of Novel Potential Therapeutic For Severe COVID-19
WILMETTE, Ill., BELOIT, Wis. and TYLER, Texas, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR) and NorthStar Medical Radioisotopes, LLC, which are jointly
Benzinga · 09/09 12:32
Monopar and NorthStar Collaborating with Texas Lung Injury Institute for Testing of Novel Potential Therapeutic for Severe COVID-19
WILMETTE, Ill., BELOIT, Wis. and TYLER, Texas, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, which are jointly developing urokinase plasminogen activator receptor targeted radio-immuno-therapeutics (uPRITs) for the potential treatment
GlobeNewswire · 09/09 12:30
The Daily Biotech Pulse: AbbVie In-licenses I-Mab's Cancer Drug, Savara Pulls The Plug On Cystic Fibrosis Study
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 3)
Benzinga · 09/04 11:28
Monopar and NorthStar Partner with Aragen for Testing of Novel Potential Therapeutic for Severe COVID-19
GlobeNewswire · 08/19 13:30
What To When You Start The Day In The Red
Following up on a trend that we’ve been seeing throughout the past few weeks, the market continues to be consistently inconsistent.
Benzinga · 08/17 13:05
Monopar Therapeutics Outlines Plan To Develop Test To Potentially Triage Coronavirus Patients Into Those Likely Versus Unlikely To Progress To Severe Respiratory Failure
Monopar Therapeutics Inc. (NASDAQ:MNPR) today announced its plan to develop a test to potentially triage COVID-19 patients into those likely versus unlikely to progress to severe respiratory failure. The test would use
Benzinga · 08/12 12:40
Monopar And NorthStar Partner With IsoTherapeutics For The Manufacturing Of Potential Therapeutic For Severe COVID-19
WILMETTE, Ill. and BELOIT, Wis. and ANGLETON, Texas, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR) (Wilmette, IL) and NorthStar Medical Radioisotopes, LLC (Beloit, WI), who are collaborating
Benzinga · 08/10 12:47
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MNPR. Analyze the recent business situations of Monopar Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MNPR stock price target is 31.00 with a high estimate of 42.00 and a low estimate of 11.00.
EPS
Institutional Holdings
Institutions: 9
Institutional Holdings: 56.77K
% Owned: 0.53%
Shares Outstanding: 10.74M
TypeInstitutionsShares
Increased
1
828
New
6
37.99K
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About MNPR
Monopar Therapeutics Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing therapeutics for cancer patients. Its pipeline includes Validive, Camsirubicin and MNPR-101. Validive is a clonidine mucobuccal tablet (clonidine MBT). Validive is designed to be used prophylactically to reduce the incidence, delay the time to onset, and decrease the duration of severe oral mucositis in patients undergoing chemoradiotherapy for oropharyngeal cancer. Its second product candidate, Camsirubicin, is a novel analog of doxorubicin. Camsirubicin is designed to reduce the cardiotoxic side effects generated by doxorubicin while retaining anti-cancer activity. MNPR-101 is a humanized monoclonal antibody designed to bind a specific cell surface receptor found on cancer cells, the urokinase plasminogen activator receptor (uPAR), and to interrupt several pathways required for tumor growth and progression. It is developing MNPR-101 for the treatment of advanced cancers.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Monopar Therapeutics Inc stock information, including NASDAQ:MNPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MNPR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MNPR stock methods without spending real money on the virtual paper trading platform.